Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma

Cancer

Volumn 94, Issue 8, 2002, Pages 2174-2179

  Delioukina, Maria L ^a   Prager, Diane ^a   Parson, Mandy ^a   Hecht, J Randolph ^a   Rosen, Peter ^a   Rosen, Lee S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Amifostine; Chemoprotection; Chemotherapy; Colorectal carcinoma; Irinotecan

Indexed keywords

AMIFOSTINE; CISPLATIN; IRINOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SCORING SYSTEM; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PILOT PROJECTS;

EID: 0037089642     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10432     Document Type: Article

References (23)

1. The current status of camptothecin analogues as antitumor agents
2. CPT-11 in gastrointestinal cancer
3. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
4. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
5. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
6. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure for patients with metastatic colorectal cancer
7. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
8. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomized trial
9. Irinotecan in the treatment of colorectal cancer: Clinical overview
10. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
11. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment
12. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine
13. Phase I/II trials of WR-2721 and cis-platinum
14. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial
15. Intracolonic WR-2721 protection of the rat colon from acute radiation injury
16. The effect of S-2(3 aminopropylamino) ethylphosphorothioic acid (WR-2721) on intestinal crypt survival
17. Efficacy and toxicity of irinotecan in patients with colorectal cancer
18. Alternative dosing schedules for irinotecan
19. Phase II study of irinotecan (CPT-11) 250 mg/m2 given every-other-week in previously treated colorectal cancer patients
20. Guidelines for administration of amifostine
21. Characterization and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
22. Every other week irinotecan (CPT11): Results of a phase I and (PK) pharmacokinetic study
23. A randomised phase II multicenter trial of irinotecan (CPT-11) using different schedules in patients with metastic colorectal cancer